Edition:
United Kingdom

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

10.36USD
14 Dec 2018
Change (% chg)

$0.39 (+3.91%)
Prev Close
$9.97
Open
$9.86
Day's High
$10.41
Day's Low
$9.77
Volume
125,517
Avg. Vol
69,331
52-wk High
$20.55
52-wk Low
$9.66

Latest Key Developments (Source: Significant Developments)

Stemline Therapeutics Announces That EMA Grants Accelerated Assessment For Planned Elzonris MAA
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Stemline Therapeutics Inc ::STEMLINE THERAPEUTICS ANNOUNCES THAT EUROPEAN MEDICINES AGENCY (EMA) GRANTS ACCELERATED ASSESSMENT FOR PLANNED ELZONRIS MARKETING AUTHORIZATION APPLICATION (MAA).STEMLINE THERAPEUTICS - EMA GRANTED ACCELERATED ASSESSMENT FOR UPCOMING CENTRALIZED MAA, WHICH STEMLINE EXPECTS TO COMPLETE IN Q1 2019.STEMLINE THERAPEUTICS -BLA FOR ELZONRIS IN BPDCN RECEIVED PRIORITY REVIEW STATUS FROM U.S. FDA, WITH TARGET ACTION DATE OF FEB 21, 2019, UNDER PDUFA.  Full Article

Stemline Therapeutics Announces That FDA Accepts Elzonris Biologics License Application
Monday, 13 Aug 2018 

Aug 13 (Reuters) - Stemline Therapeutics Inc ::STEMLINE THERAPEUTICS ANNOUNCES THAT FDA ACCEPTS ELZONRIS™ BIOLOGICS LICENSE APPLICATION (BLA) AND GRANTS PRIORITY REVIEW.STEMLINE THERAPEUTICS INC - FDA ALSO GRANTED PRIORITY REVIEW FOR BLA AND HAS SET A TARGET ACTION DATE OF FEBRUARY 21, 2019, UNDER PDUFA.  Full Article

Stemline Therapeutics reports Q3 loss per share $0.68
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.68.Q3 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Stemline Therapeutics-‍stemline ended Q3 of 2017 with $79.9 million in cash, cash equivalents and investments, as compared to $93.2 million as of June 30, 2017​.  Full Article

Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​.Stemline Therapeutics Inc - ‍based on feedback from U.S. FDA, co remains on track to begin submission of BLA in 4Q17-1Q18 timeframe for SL-401​.  Full Article

Stemline Therapeutics Q4 loss per share $0.56
Thursday, 16 Mar 2017 

Stemline Therapeutics Inc : Stemline therapeutics reports fourth quarter 2016 financial results . Q4 loss per share $0.56 . Q4 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S .Qtrly grant revenue $299,401 versus $205,651.  Full Article